X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Jemperli (dostarlimab) is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.
Lead Product(s): Dostarlimab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sagard Healthcare
Deal Size: $50.0 million Upfront Cash: $50.0 million
Deal Type: Agreement May 09, 2024
Details:
ANB019 (imsidolimab) is a fully humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, that is being developed for the treatment of GPP.
Lead Product(s): Imsidolimab
Therapeutic Area: Dermatology Product Name: ANB019
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2024
Details:
Under the terms of the agreement, Anaptys will receive from Centessa an exclusive, global license for ANB101 (CBS004), a potentially best-in-class BDCA2 modulator antibody that targets pDCs and ANB102, an extended half-life BDCA2 modulator.
Lead Product(s): CBS004
Therapeutic Area: Immunology Product Name: ANB101
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Centessa Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $10.0 million
Deal Type: Licensing Agreement November 27, 2023
Details:
ANB019 (imsidolimab) is a fully humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, that is being developed for the treatment of GPP.
Lead Product(s): Imsidolimab
Therapeutic Area: Dermatology Product Name: ANB019
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
JEMPERLI (dostarlimab-gxly) is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.
Lead Product(s): Dostarlimab-gxly,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
Jemperli (dostarlimab-gxly) is a PD-1-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. It is being investigated for mismatch repair-deficient/microsatellite instability-high locally advanced rectal cancer.
Lead Product(s): Dostarlimab-gxly,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
ANB030 (Rosnilimab), its investigational wholly owned PD-1 agonist, demonstrates best-in-class activity in vitro with superior inhibition of T cell proliferation, reduction in inflammatory cytokine secretion (Th1, Th2, Th17) and depletion of PD-1+ T cells.
Lead Product(s): Rosnilimab
Therapeutic Area: Dermatology Product Name: ANB030
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.
Lead Product(s): Dostarlimab
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2022
Details:
Full results from the PERLA phase II trial, including the primary endpoint of ORR and the key secondary endpoint of progression-free survival, with results by programmed death ligand-1 (PD-L1) expression subgroups.
Lead Product(s): Dostarlimab,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
ZEJULA having niraparib, is the only once-daily oral first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy.
Lead Product(s): Niraparib Tosylate
Therapeutic Area: Oncology Product Name: Zejula
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: DRI Healthcare Trust
Deal Size: $45.0 million Upfront Cash: $35.0 million
Deal Type: Divestment September 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
